Organon & Co
Track in portfolio
Price chart
Description
Company and Business Model
Organon & Co is a global healthcare company focused on women's health, biosimilars, and established medicines. Its core products include contraceptives, hormone therapies, and treatments for various chronic conditions. The company operates primarily in women's health and biosimilars, with major revenue sources stemming from its portfolio of prescription medications and healthcare solutions. Organon aims to address unmet medical needs and improve health outcomes for women.
Investment Profile
The investment profile of Organon & Co is more aligned with balanced investors, given its modest dividend yield and stable revenue streams. The company has shown some volatility and a recent decline in revenue, which may appeal to those seeking a mix of growth and income. The stock's characteristics suggest it may be suitable for investors looking for moderate risk and potential for steady returns over time.
Fundamental metrics (experimental) Updated: 2026-07-26
- EPS (TTM) — earnings per share for the last 12 months, $
- 0.95
- Revenue QoQ — quarter-over-quarter revenue growth
- -3.1%
- EPS surprise
- -14.5%
- 20d volatility
- 0.2%
- Dividend yield
- 0.6%
- last ex-date
- 2026-05-11
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-07-19 | Hold | Sell | Weak fundamentals and mixed momentum signal caution. |
| 2026-07-11 | Sell | Hold | Weak fundamentals and mixed momentum signal caution. |
| 2026-06-13 | Hold | Sell | Weak fundamentals and mixed momentum signal caution. |
| 2026-06-05 | Sell | Hold | Weak fundamentals and mixed momentum signal caution. |
| 2026-05-28 | Hold | Sell | Weak fundamentals and negative momentum raise concerns. |
| 2026-05-08 | — | Hold | Weak fundamentals and high volatility raise concerns. |
| 2026-05-08 | Hold | Hold | Компания показала значительный рост за последние 20, 60 и 120 дней, однако негативные показатели по выручке и сюрпризам указывают на потенциальные риски. Рекомендуется удерживать акции до более ясной картины финансовых р |
| 2026-04-29 | — | Hold | Компания демонстрирует значительный рост за последние 20 и 120 дней, что указывает на позитивные тренды. Несмотря на небольшое снижение выручки, потенциал роста и текущая цена делают акцию привлекательной для покупки. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-04-27 | Piper Sandler | Rating Upgraded | — → 14 | 13.175 |
| 2026-04-10 | BNP Paribas | Update | — → 12 | 8.685 |
| 2026-02-24 | Barclays | Target Raised | 7.5 → 8 | 7.92 |
| 2025-12-08 | Barclays | Update | — → 7.5 | 7.29 |
| 2025-10-27 | Piper Sandler | Update | — → 5 | 7.13 |
News Page 1 of 1
Nothing yet